COMMUNIQUÉS West-GlobeNewswire

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
23/04/2026
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices [...]
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026 [...]
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
23/04/2026
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit [...]
Q1 2026 revenue
23/04/2026
Q1 2026 revenue Quarterly activity Revenue: €177.4m, up 2.6% at CER 1 and on a like-for-like basis 2 Increase driven by EMEA (+4.5%), with an improvement in the situation in France, and by Asia (+6.0%); a decline in the [...]
Catheter Precision to Attend and Share New Clinical Data at the 47th Annual Heart Rhythm Society Meeting
23/04/2026
VIVO System to be featured in educational sessions at HRS Accepted manuscripts for LockeT and VIVO are now published and available online FORT MILL, S.C., April 23, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. ( [...]
FSR, in Partnership with ATS, Welcomes Dr. Matt Craig to Drive Strategic Research Initiatives
23/04/2026
CHICAGO, April 23, 2026 (GLOBE NEWSWIRE) -- Through the long-standing collaboration between Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS), FSR and ATS are pleased to announce that [...]
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
23/04/2026
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint [...]
First-quarter 2026 revenue
23/04/2026
Press release Revenue as at 31 March 2026 stood at €1 , 336m , up +4.9% on an organic basis compared with the first quarter of 2025 All business segments and regions contributed to revenue growth, supported by [...]
Chiffre d’affaires du 1er trimestre 2026
23/04/2026
Chiffre d’affaires du 1 er trimestre 2026 Activité trimestrielle Chiffre d’affaires : 177,4 M€, en hausse de 2,6% à TCC 1 et périmètre comparable 2 Une évolution portée par l'EMEA (+4,5 %), avec une amélioration de la [...]
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses
23/04/2026
TUSCALOOSA, Ala., April 23, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral asset portfolio, establishing the Company [...]
Chiffre d'affaires du 1er trimestre 2026
23/04/2026
Communiqué de presse Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m , en progression de +4,9% en base organique par rapport au 1 er trimestre 2025 L’ensemble des activités et des régions contribue à la [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2026
23/04/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
23/04/2026
Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction [...]
IMAAVY® (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
23/04/2026
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained [...]
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
23/04/2026
PARAMUS, NJ, April 23, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage [...]
Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
23/04/2026
Tilray Medical Poised to Accelerate U.S. Medical Cannabis Access for Patients NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.  (“Tilray”, “our”, “we” or the “Company”) (NASDAQ: TLRY; TSX: TLRY), a [...]
MAPS Celebrates 40 Years at a Defining Moment for Psychedelics
23/04/2026
Founded in April 1986 to advance psychedelic research and knowledge, MAPS has raised more than $150 million, supported 45 studies, and shaped the global policy and cultural landscape of psychedelics. As science, policy [...]
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
23/04/2026
Expect to report topline data from both studies mid-2026 SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage [...]
Codexis to Report First Quarter 2026 Financial Results on May 7
23/04/2026
REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it [...]

Pages